Taysha Gene Therapies, Inc. - 8-K Filing
Taysha Gene Therapies held its annual stockholder meeting on June 1, 2026. Shareholders voted to elect two directors (Sean P. Nolan and Laura Sepp-Lorenzino), ratified Deloitte & Touche LLP as auditors with near-unanimous support, approved executive compensation advisory votes with 41% against, and indicated a preference for annual say-on-pay votes. (Items: 5.07 Submission of Matters to a Vote of Security Holders)
Tickers: $TSHA